Optimizing Combination Strategies for Effective Inhibition of the MAPK Pathway in RAS-Driven Cancers
- Downstream alterations in the RAS MAPK pathway drive resistance to RAS inhibitors in the clinic
- NST-628 is a highly efficacious non-degrading pan-RAF-MEK molecular glue with broad activity in RAS-mutant cancers
- NST-628 is a promising combination anchor in KRAS-mutant cancers